CAJ | 학술논문

目的：观察多巴丝肼(美多芭)对伴有尿毒症不宁腿综合征( RLS)患者的治疗效果。方法对符合尿毒症及RLS诊断标准的46例患者，随机分成2组：治疗组23例，给予多巴丝肼治疗；对照组23例，给予阿普唑仑治疗；观察治疗后2、4周的国际不宁腿综合征研究组( IRLSSG)调查问卷评分及匹茨堡睡眠质量指数量表( PSQI)评分变化。结果2组治疗后IRLSSG评分均较治疗前明显下降，治疗组由治疗前的(22.74±7.30)分降到4周后的(13.04±7.06)分，对照组由治疗前的(20.87±7.31)分降到4周后的(17.74±7.28)分，治疗组IRLSSG评分较对照组下降更明显，差异有统计学意义( P <0.05)；2组治疗后PSQI评分均较治疗前明显下降，治疗组由治疗前的(16.12±4.60)分降到4周后(6.19±3.21)分，对照组由治疗前的(16.87±4.72)分降到4周后的(9.35±4.15)分，治疗组PSQI评分较对照组下降更加明显，差异有统计学意义( P <0.05)；2组均无明显不良反应。结论多巴丝肼治疗伴有尿毒症的不宁腿综合征安全有效。
목적：관찰다파사정(미다파)대반유뇨독증불저퇴종합정( RLS)환자적치료효과。방법대부합뇨독증급RLS진단표준적46례환자，수궤분성2조：치료조23례，급여다파사정치료；대조조23례，급여아보서륜치료；관찰치료후2、4주적국제불저퇴종합정연구조( IRLSSG)조사문권평분급필자보수면질량지수량표( PSQI)평분변화。결과2조치료후IRLSSG평분균교치료전명현하강，치료조유치료전적(22.74±7.30)분강도4주후적(13.04±7.06)분，대조조유치료전적(20.87±7.31)분강도4주후적(17.74±7.28)분，치료조IRLSSG평분교대조조하강경명현，차이유통계학의의( P <0.05)；2조치료후PSQI평분균교치료전명현하강，치료조유치료전적(16.12±4.60)분강도4주후(6.19±3.21)분，대조조유치료전적(16.87±4.72)분강도4주후적(9.35±4.15)분，치료조PSQI평분교대조조하강경가명현，차이유통계학의의( P <0.05)；2조균무명현불량반응。결론다파사정치료반유뇨독증적불저퇴종합정안전유효。
Objective To observe the effect of madopar on uremia patients with restless legs syndrome ( RLS ) . Methods Forty-six patients with uremia and RLS were randomly divided into 2 groups: the treatment group with 23 cases, given madopar treatment;control group with 23 cases, given alprazolam;2, 4 weeks after treatment, the effect were observed by using the International Restless Legs Syndrome Study Group ( IRLSSG ) ’ s questionnaire score and the Pittsburgh sleep quality index ( PSQI) score. Results The 2 groups of patients after treatment, IRLSSG score were significantly decreased than before treatment, the treatment group from (22. 74 ± 7. 30) points decreased to (13. 04 ± 7. 06) points after 4 weeks of treatment, the control group from (20. 87 ± 7. 31) points down to (17. 74 ± 7. 28) points after 4 weeks of treatment, IRLSSG score of the treatment group were decreased more significantly than in the control group, the difference was statistically signifi-cant ( P <0. 05);the 2 groups of patients after treatment, PSQI score were significantly decreased than before treatment, the treatment group decreased from (16. 12 ± 4. 60) points to after 4 weeks’ (6. 19 ± 3. 21) points, the control group decreased from before treatment’s (16. 87 ± 4. 72) points to 4 weeks’ (9. 35 ± 4. 15) points, PSQI score of the treatment group were decreased more significantly than in the control group, the difference was statistically significant ( P <0. 05);no obvious ad-verse reaction were found in the 2 groups. Conclusion Madopar is safe and effective for treatment of uremia patients with restless legs syndrome.